about
The complement system as a potential therapeutic target in rheumatic disease.Cell-bound complement activation products in SLE.Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy.Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.The role of complement components C1q, MBL and C1 inhibitor in pathogenesis of endometriosis.The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Complement in Lupus Nephritis: New Perspectives
@ast
Complement in Lupus Nephritis: New Perspectives
@en
Complement in Lupus Nephritis: New Perspectives
@nl
type
label
Complement in Lupus Nephritis: New Perspectives
@ast
Complement in Lupus Nephritis: New Perspectives
@en
Complement in Lupus Nephritis: New Perspectives
@nl
prefLabel
Complement in Lupus Nephritis: New Perspectives
@ast
Complement in Lupus Nephritis: New Perspectives
@en
Complement in Lupus Nephritis: New Perspectives
@nl
P2093
P2860
P356
P1476
Complement in Lupus Nephritis: New Perspectives
@en
P2093
Patrick N Cunningham
Richard J Quigg
P2860
P356
10.1159/000431278
P407
P577
2015-09-01T00:00:00Z